Qiagen N.V.
QGENHealthcareNASDAQDiagnostics & Research · Last scanned Jun 2, 2026
Scan Results
Daily timeframeQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. At a $7.46B market cap, Qiagen N.V. ranks as a mid-cap company within healthcare. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
Market Cap
$7.46B
Beta
0.64
P/E (TTM)
18.46
P/E (Fwd)
13.73
EPS (TTM)
$1.96
EPS (Fwd)
$2.64
ROE
11.9%
ROA
6.0%
Cash
$646.3M
Total Debt
$1.67B
Free CF
$238.9M
52W Change
-20.1%
Annual Financials
Cash vs Debt
On the balance sheet, QGEN has $646.3M in cash with $1.67B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $238.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.9% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.14B (2022) to $2.09B (2025).
With a beta below 0.7, Qiagen N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing QGEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.